Xtx Topco LTD Crispr Therapeutics Ag Transaction History

Xtx Topco LTD

$1.81 Billion
Q1 2025

A detailed history of Xtx Topco LTD transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Xtx Topco LTD holds 10,907 shares of CRSP stock, worth $395,815. This represents 0.02% of its overall portfolio holdings.

Number of Shares

10,907

Previous 8,919 22.29%

Holding current value

$395,815

Previous $351,000 5.7%

% of portfolio

0.02%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$34.03 - $53.02 $67,651 - $105,403	1,988 Added 22.29%	10,907 $371,000
Q4 2024 Feb 13, 2025	SELL	$38.65 - $55.15 $815,630 - $1.16 Million	-21,103 Reduced 70.29%	8,919 $351,000
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $999,577 - $1.41 Million	22,402 Added 293.99%	30,022 $1.41 Million
Q2 2024 Aug 12, 2024	SELL	$51.17 - $68.18 $157,143 - $209,380	-3,071 Reduced 28.73%	7,620 $411,000
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $414,194 - $608,422	6,827 Added 176.68%	10,691 $728,000
Q4 2023 Feb 13, 2024	SELL	$38.62 - $72.18 $698,751 - $1.31 Million	-18,093 Reduced 82.4%	3,864 $241,000
Q3 2023 Nov 13, 2023	BUY	$45.39 - $59.0 $298,802 - $388,397	6,583 Added 42.82%	21,957 $996,000
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $668,307 - $1.04 Million	15,374 New	15,374 $863,000
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $226,222 - $386,352	5,233 New	5,233 $318,000
Q4 2021 Feb 11, 2022	SELL	$70.09 - $111.29 $508,012 - $806,629	-7,248 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $294,234 - $418,228	2,670 Added 58.32%	7,248 $811,000
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $461,645 - $741,132	4,578 New	4,578 $741,000

Others Institutions Holding CRSP

# of Institutions

479

Shares Held

64.2M

Call Options Held

2.15M

Put Options Held

1.92M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $2.83B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account